0001209191-18-030058.txt : 20180514
0001209191-18-030058.hdr.sgml : 20180514
20180514193432
ACCESSION NUMBER: 0001209191-18-030058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180510
FILED AS OF DATE: 20180514
DATE AS OF CHANGE: 20180514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REED ELIZABETH E
CENTRAL INDEX KEY: 0001283303
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 18832598
MAIL ADDRESS:
STREET 1: 9050 CAMINO SANTA FE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Retrophin, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 760-260-8600
MAIL ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-10
0
0001438533
Retrophin, Inc.
RTRX
0001283303
REED ELIZABETH E
C/O RETROPHIN, INC.
3721 VALLEY CENTRE DR., SUITE 200
SAN DIEGO
CA
92130
0
1
0
0
SVP, GC & Corporate Secretary
Common Stock
2018-05-10
4
A
0
7000
0.00
A
17827
D
Employee stock option (right to buy)
25.25
2018-05-10
4
A
0
42000
0.00
A
2028-05-09
Common Stock
42000
42000
D
Performance-based restricted stock units
2018-05-10
4
A
0
7000
0.00
A
Common Stock
7000
7000
D
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2018-05-14